Related Experiment Video
Updated: Mar 12, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.3K
Personalized medicine in rheumatology
Anna Kłak1, Agnieszka Paradowska-Gorycka2, Brygida Kwiatkowska3
1Department of Gerontology and Public Health, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Reumatologia
|November 10, 2016
Summary
Rheumatoid arthritis (RA) requires early diagnosis and treatment with disease-modifying drugs like methotrexate (MTX) to prevent joint damage. Personalized medicine through pharmacogenetics may improve treatment outcomes for this heterogeneous disease.
Area of Science:
- Rheumatology
- Genetics
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a complex and heterogeneous autoimmune disease with variable clinical presentations and treatment responses.
- Despite advances, RA remains poorly understood in the 21st century, highlighting the need for improved diagnostic and therapeutic strategies.
- Early diagnosis and prompt initiation of disease-modifying antirheumatic drugs (DMARDs), with methotrexate (MTX) as the current standard, are critical to prevent irreversible joint destruction and functional decline.
Approach:
- Exploration of pharmacogenetic and pharmacogenomic studies to elucidate individual patient genetic profiles.
- Focus on identifying disease-specific genes in the early stages of RA, before the onset of autoimmune aggression.
- Leveraging genetic information to advance towards personalized medicine approaches for RA management.
Key Points:
- Heterogeneity of rheumatoid arthritis necessitates tailored treatment strategies.
- Methotrexate (MTX) is the gold standard DMARD for early RA treatment.
- Pharmacogenetics and pharmacogenomics offer pathways to personalized RA medicine.
Conclusions:
- Personalized medicine, guided by genetic profiling, holds promise for optimizing RA treatment.
- Further research into RA-specific genes is essential for early intervention and preventing disease progression.
- Improved understanding of RA's genetic underpinnings can lead to better patient outcomes and reduced disease burden.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:21Rheumatic Heart Disease III: Medical Management
450
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
450
01:11Genome-wide Association Studies-GWAS
16.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.4K
01:24Dosage Regimen: Individualization
255
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
255
01:29Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83